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Integrating stages of change models to cast new
vision on interventions to improve global
retinoblastoma and childhood cancer outcomes
Meaghann S Weaver1,2*, Christina L Heminger2 and Catherine G Lam1,3

Abstract
Background: Retinoblastoma, the most common intraocular tumor globally, represents a curable cancer when
diagnosed early and treated promptly. Delay to diagnosis, lag time prior to treatment initiation, and abandonment
of treatment including upfront treatment refusal, represent stark causes of high retinoblastoma mortality rates in
low- and middle- income settings, particularly regions in Africa. While a health delivery-based approach has been a
historic focus of retinoblastoma treatments globally and is essential to quality care, this is necessary but not adequate.
Retinoblastoma is a compelling disease model to illustrate the potential insights afforded in theory-informed approaches
to improve outcomes that integrate public health and oncology perspectives, prioritizing both health service delivery
and social efficacy for cure.
Discussion: Given that barriers to appropriate and timely diagnosis and treatment represent main contributors to
mortality in children with retinoblastoma in resource-limited settings such as certain areas in Africa, an important priority
is to overcome barriers to cure that may be predominantly socially influenced, alongside health delivery-based
improvements. While Stages of Change models have been effectively utilized in cancer screening programs within
settings of economic and cultural barriers, this application of health behavior theory has been limited to cancer
screening rather than a comprehensive framework for treatment completion. Using retinoblastoma as a case example,
we propose applying stage-based intervention models in critical stages of care, such as the Precaution Adoption
Process Model to decrease delay to diagnosis and a Transtheoretical Model to increase treatment completion rates
in resource-limited settings.
Summary: Stage-based theories recognize that improved cure and survival outcomes will require supportive strategies
to progress households, communities, and social and economic institutions from being unaware and unengaged to
committed and sustained in their respective roles. Applying a stage-based model lens to programmatic interventions in
resource-limited settings has potential for visible improvement in outcomes for children with retinoblastoma and
other cancers.
Keywords: Retinoblastoma, Pediatric oncology, Stages of change model, Resource-limited settings, Interventions,
Diagnostic barriers, Treatment barriers, Social efficacy
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Background
Global priority based on incidence

Retinoblastoma represents the most common pediatric
intraocular cancer with the greatest disease burden in
populations with high birth rates. Across the globe, there
are 9,000 new diagnoses of retinoblastoma estimated
annually, or approximately one case per 15000 live
births, with the majority in resource-limited settings [1].
Hospital- based studies in India suggest that this intraocular cancer may comprise up to 10-15% of all diagnosed
childhood cancers in parts of India, in contrast to most
developed settings where it accounts for less than 5% of
pediatric cancers [2]. The varying reported incidence of
retinoblastoma within countries likely reflects reporting
mechanisms more than true incidence difference [3,4].
Retinoblastoma has been reported as the most frequent
solid tumor diagnosis in Mexico after central nervous
system neoplasms [5] and in northern Nigeria, retinoblastoma is documented as the most common childhood
malignancy overall, accounting for almost one-third of
all pediatric oncology cases [6]. Retinoblastoma has been
documented among the top three childhood cancers
diagnosed in Tanzania, Ghana, the Congo, and Kenya
and as the fourth most common in Senegal [7-11]. The
documented recognition of retinoblastoma in low- and
middle-income settings (LMIS) is believed to underrepresent the actual number of cases [9,12].
Among areas with lower overall detection of childhood
cancers, there is an apparent high incidence in advanced
stage retinoblastoma being reported [13]. This eye tumor
progresses through signs that can be relatively subtle,
such as strabismus (abnormal eye alignment often
resulting in a squint), to leukocoria (white light reflex, which can be readily recognized by alert family and
community members), to more advanced orbital inflammation, proptosis (orbital bulge) and bulky protruding
extraocular masses literally staring at an observer both in
community and clinical settings, accompanied by distant
disease spread [14]. Retinoblastoma may therefore be
more amenable to reporting in low- and middle-income
settings globally as compared with other childhood oncologic diagnoses in these same settings that may be more
heavily resource- or technology-dependent.
Extent and impact of delay

Retinoblastoma represents a curable cancer when caught
early. Whether the lag time is due to delay in diagnosis
or due to delay in treatment initiation (Figure 1),
population-based studies reveal extended delays in
access to cure in many LMIS. As an example, we explored
quantified pediatric retinoblastoma lag times as reported
in the continent of Africa through a comprehensive literature review and direct author contact for additional information regarding both published and unpublished data,
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with data available for 10 countries detailed (Figure 2).
Mean time from symptom onset to diagnosis was reported by retrospective chart reviews as 6 months in
Nigeria (n = 26) [15], 10 months in Tunisia (n = 35) [16],
8 months in Tanzania (n = 91) [17], and over 24 months in
Mali (n = 50) [18]. A delay of more than six months from
the first clinical sign of retinoblastoma to diagnosis is associated with assured extraocular spread and 70% mortality
[3]. Of the cases of retinoblastoma diagnosed over a fiveyear period in central Africa, over 90% of the patients presented to the retinoblastoma center after extraocular
spread [19]. In Kenya, where the delay from retinoblastoma symptom onset to diagnosis is a mean of 6.8 months,
the mortality of retinoblastoma is 73% [20], which is over
50 times higher than that in Canada (1%) [21]. Approximately half to three-fourths of children diagnosed with
retinoblastoma in Africa die, presumably due to diagnosis
at an advanced stage, while 3-5% of children with retinoblastoma die in the United States and Europe, presumably
in part due to earlier diagnosis alongside comprehensive
management [3]. While current treatment emphasis in
high-income countries focuses on vision-sparing interventions, the priority in LMIS remains the life-saving interventions of prompt diagnosis and treatment. A tri-modal
depiction of delay (Figure 3) acknowledges that a conglomeration of health service delivery and social efficacy
promotion must be established in the steps from first
symptom recognition to diagnosis to urgent treatment
initiation [22].
Medical factors interplay with complex and shifting
social dynamics. As health delivery systems improve and
as medical care advances, the management of retinoblastoma shifts from the basic priority of saving the life
of the child with retinoblastoma, to include prioritization
of ocular salvage. While the Stages of Change model we
detailed here emphasizes early recognition and acceptance of enucleation (a survival priority) that may best apply
to late presenting retinoblastoma in resource-limited settings, components and applications of this model may be
adapted for other heterogeneous contexts. For instance,
in contexts with earlier presentations and additional resources, consideration of the best interests of the child with
intraocular disease may warrant weighing the continuum
of readiness for intra-arterial or systemic therapy (an ocular
salvage priority), and recognizing the perceptions and barriers that may affect uptake of these therapies where appropriate and available. Rather than view theory as a rule
equally applicable in all settings, informed application of
theory recognizes the unique and complex dimensions of
the social and medical decisional continuums.
Barriers to diagnosis

Health service delivery barriers to earlier diagnosis in
LMIS include lack of universal health insurance for
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Figure 1 Delineating lag time. Delineating total lag time (red) prior to initiation of curative therapy as composed of delay to diagnosis (purple)
and delay to treatment initiation (blue).

Figure 2 Duration (in months) of delays to retinoblastoma treatment in Africa. L = Delay from symptom to treatment, D1 = Delay from symptom
onset to diagnosis, D2 = Delay from diagnosis to treatment initiation. * = month duration obtained through personal communication with authors and
included with authors’ kind permission (unpublished data). Cameroon L = 24 months, n = 57 (Kagmeni2013*) [23]. Congo L = 24 months, n = 49
(Lukusa2012) [9]. Nigeria D1 = 6.3 months, n = 26 (Bekibele2009) [24]. Tanzania D1 = 10 months, n = 91 (Bowman2008) [17]. Mali D1 = 50 months, n = 55
(Boubacar2010) [18]. Tunisia D1 = 10 months, n = 35 (Frikha2009) [16]. Namibia D2 = 3.5 months, n = 15 (Wessels1996) [25]. Sudan D1 = 10 months, n = 25
(Ali2011) [26]. Burkina Faso, D1 = 11 months, n = 3 (Nikiema2009) [27]. Kenya D1 = 6.8 months, n = 206 (Nyamori2012*) [20].
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Figure 3 Tri-lineage model of delay with description of possible causation.

non-communicable diseases, missing links in multidisciplinary inclusion, constraints in procurements of diagnostic supplies, and inefficiencies within the referral
system [24]. Local community health workers or general
care providers may not have the referring mechanism
readily in place to expedite a family’s access to diagnosis. Social barriers to receipt of a diagnosis include a
myriad of educational, cultural, and economic influences. Lack of parental education and low awareness of
the signs and symptoms of retinoblastoma can delay
families from seeking medical attention [28]. Parents
may fear judgment from the medical team if the retinoblastoma symptoms have progressed to the point of
disfiguration prior to presentation to care. Even when a
family does recognize the signs of retinoblastoma, some
families may believe eye cancer is incurable and therefore select not to seek medical care (cancer fatalism)
[10]. Chart assessments of causes for delay to retinoblastoma diagnosis in LMIS describe parental reliance
on traditional healers or prayer camps for initial treatment due to available access and cultural prioritization
[9,29,30], as belief-system has clear impact on care
seeking [31,32]. Conflicting priorities, to include survival priorities such as food or school fees for other siblings, may realistically serve as barriers to pursuit of a
diagnosis. Parents may not be able to fund diagnostic
procedures. Parents may also not have means of transport
to medical centers due to prohibitive travel time, transportation fees, or lack of reliable or safe roads. Regional conflict and political strife risk disrupting vital health services
and supply chains, which urges attentiveness to the needs

of children with chronic conditions during times of acute
conflict [33].
Barriers to treatment initiation and completion

Despite receipt of a retinoblastoma diagnosis, the child’s
life is jeopardized if necessary treatment is delayed [34].
Health service delivery barriers to earlier treatment initiation in LMIS include lack of cost coverage for curativedirected treatments; shortage of personnel; fragmented
or delayed hand-offs between multi-disciplinary team
members such as general providers, pathologists, oncologists, surgeons; constraints in access to surgical supplies;
and medication shortages [24]. Even if the health delivery
system was fluid and efficient, the cultural context of partnership, education, and enablement between families and
providers remains critical. A family’s understanding of the
treatment plan and trust in the health team remains a vital
component to treatment efficacy and psychosocial wellness
[35]. Refusal of enucleation (removal of the eye globe) has
been documented as a main obstacle to cure in up to
40% of all patients diagnosed with retinoblastoma in lowincome settings [36]. Families in some LMIS may reject
enucleation as curative treatment because of actual or perceived social stigma or poor understanding of the high
quality of life possible after unilateral enucleation [4]. A
retrospective review of enucleation refusal from Nigeria reported >10% (3/26) upfront enucleation refusal rate and
42% abandonment rate prior to enculeation (11/23) [24].
Investigation of attitudes regarding blindness in Africa reveal continued prevalence of stigma attached to eye loss,
particularly in rural communities [37,38]. Furthermore,
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delays during treatment and treatment abandonment
may adversely affect a dominant proportion of patients
in resource-limited settings [14,34,39]. Ultimately, delays
in diagnosis and treatment that result in more advanced,
extraocular disease are unfortunately associated with requirements for more intensive therapy and expertise with
greater demand for resources, higher morbidity and less
chance of cure and survival. Children diagnosed early with
disease well-confined within the eye, however, can often
be saved with simpler surgical enucleation alone, thus addressing barriers to timely treatment have great potential
to save resources as well as patients’ lives.
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partnerships and resources that would be effective within
this cultural and cost-context. Development of educational resources for health care providers occurs in the
planning phase. During implementation, a public health
approach frames the strategies and materials utilized.
Whereas success in strictly medical models is traditionally defined through calculation of inputs, outputs, and
outcomes obtained at the conclusion of a project, a public health model encourage continuous quality improvement via feedback loops throughout the iterative stages
of design, planning, implementation, and evaluation.

Discussion
Purpose statement

Viewing pediatric oncology interventions, such as retinoblastoma diagnosis and treatment interventions, through a
comprehensive public health lens provides opportunity for
new insights. A public health model (Table 1) can be applied to guide all programmatic steps from defining the
problem through to intervention planning, implementation, and evaluation [40]:
During the definition phase, a public health approach
surveys community awareness regarding retinoblastoma,
attitudes regarding cancer susceptibility and severity, and
extent of blindness stigma. The definition phase necessarily investigates baseline cancer knowledge and referral
trends of local health care providers [5]. The public health
model then assesses available local resources and analyzes
barriers to patient and provider efficacy. During the
planning phase, a public health approach prioritizes
Table 1 Public health approach to retinoblastoma
Programmatic phase Public health approach
Definition phase

● Survey community awareness regarding
retinoblastoma [41]
● Monitor baseline knowledge of healthcare
providers [5]
● Assess attitudes regarding cancer susceptibility
and severity
● Determine extent of blindness stigma within
community
● Assess available local resources
● Determine barriers to patient and provider
efficacy

Planning phase

● Prioritize partnerships and resources that would
be effective within this cultural and cost-context
● Prepare educational intervention for healthcare
provider referral sources

Implementation phase ● Frame the strategies and materials within local
context
● Implement cancer curricular for healthcare
providers
Evaluation

● Continually improve quality via feedback loops
during each stage

Innovation of stages of change-based approach
to retinoblastoma

While the innovative emphasis of this paper is to target Stages of Change models for earlier retinoblastoma
diagnosis and treatment, effective intervention programs
would be blind to reality to not concurrently prioritize
health delivery improvements such as creation of multidisciplinary care teams, central pathology review, referral system logistics strengthening, uniform treatment protocols,
reliable access to supplies and medications, cost coverage
for treatment, and provision of transportation and housing.
Establishment of twinning (collaboration and support partnership) programs in Guatemala and Jordan and development of integrated multidisciplinary services in Argentina
and India have provided documented improvements in
retinoblastoma treatment outcomes with health deliverytargeted interventions [4]. Availability of appropriate and
adequate treatment is a necessary step in overcoming treatment delay.
The ability of public health interventions to impact
retinoblastoma outcomes through community awareness
has been well-documented [41]. A campaign linking
retinoblastoma education to a national campaign in
Honduras decreased median time from symptom to
diagnosis from 7.2 months to 5.5 months and decreased
the proportion of extraocular cases at time of presentation from 73% to 35% [42]. An early diagnosis campaign
in Brazil trained public school teachers and community
health workers to recognize the symptoms of retinoblastoma, resulting in decreased extraocular disease at
time of presentation from 56% to <10% in less than
20 years [4]. Within the context of the Stages of Change
Models, these community awareness approaches are
viewed as necessary external influences, mediating the
family’s ultimate readiness for treatment.
Even the most efficient of health delivery improvements and community awareness campaigns do not
manifest effects on survival outcomes if the family remains undecided about seeking medical attention for
leukocoria or if the family refuses enucleation. Stagebased intervention models recognize that decisions to
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pursue a diagnosis and engage in treatment are complex
and involve a variety of motivations, knowledge levels,
and readiness. Stage-based interventions target supportive behavioral strategies to help families prepare for the
next decisional stage in diagnosis and treatment. Stages
of Change models have been utilized effectively in
breast, skin, colorectal, and cervical cancer screening decisional interventions to include settings of economic
and cultural barriers [43,44]. Although utilized in cancer
screening, stage-based models have not been comprehensively applied to pediatric oncology interventions
from the initial programmatic design through implementation and evaluation. A recent study describing
pediatric retinoblastoma treatment completion in India
documented family unwillingness to allow enucleation
(20%, n = 16) as the second most common cause for
treatment failure and thereby targeted the essential role
of family-directed support interventions for treatment
completion [39]. This study strategically timed interventions such as placing posters of patients successfully
treated for retinoblastoma (with emphasis on the cosmetic outcome of prostheses) in the clinic area, creating
a parent group with presence of parent experts (parents
of child survivors of retinoblastoma), and intensifying
family counseling sessions from time of initial clinic contact. These interventions were associated with resultant
steady decline in treatment abandonment rates from 71%
in 2008 to 17% in 2011 (P = 0.01) [39].
Facing system and social barriers, families should not
receive blame for delay to diagnosis, delay to treatment
initiation, or abandonment of treatment. At the same
time, these real barriers reveal opportunities to attentively
support and move families through the complex stages of
readiness for diagnosis and receipt of treatment.
Delay in time to diagnosis: method for precaution
adoption process model interventions

Leukocoria is the most common initial sign of retinoblastoma. Retinoblastoma remains intraocular and curable for the first 3-6 months after the first sign of
leukocoria, making this a most urgent time for diagnosis
before retinoblastoma spreads beyond the eye [28]. Because parents are often the first to note the ocular sign
of leukocoria [45], retinoblastoma symptom awareness
must prioritize family members. The Precaution Adoption
Processes Model (PAPM) seeks to identify the stages involved when people commence health-protective behaviors for a dichotomous action such as seeking diagnosis
for a symptom. PAPM as illustrated here presumes presence of some basic infrastructure including that to diagnosis retinoblastoma, and which in our example also
included those such as well child checks, patient navigators, psychosocial support services, and prosthetic
eye interventions. PAPM recognizes the factors that
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move people from one stage to the next, namely lack of
awareness of the first symptom to the action of obtaining
a diagnosis and, ultimately, the option for an individual to
“exit” the model through a refusal to act (in this case, obtain a diagnosis) and terminate stage change. The barriers
impeding progress toward diagnosis are targeted specifically to the decisional stage the family has reached. While
many patients in truly low-income settings may present
with metastatic disease beyond targeted interventions’
reach, recognition of variability in patients’ presentation
within a given setting as well as promotion of efforts to
address stage-specific barriers as a community can in
turn galvanize the resources and social shifts necessary.
Applied in a setting with appropriate resources, PAPM has
potential to systematically inform development of interventions to decrease the time interval from retinoblastoma
symptom onset to diagnosis by programmatically partnering with families accordingly to their expressed needs in
each decisional stage leading to diagnosis (Figure 4).
Delay in time to treatment: method for transtheoretical
model interventions

The Transtheoretical Model (TTM) seeks to identify the
stages involved when people commence health-protective
behaviors and recognizes the factors that move people
from one stage to the next, ranging from Precontemplation
where the family is either unaware or unengaged in making
a behavioral change, to Maintenance, where Action is sustained over a period of time. The model allows for relapse
and re-entry in recognizing that behavior change is complex and non-linear; additionally, the theory authors have
identified processes of change that exemplify movement
from one stage to another (Figure 5).
A very large proportion of patients in low-income
settings present with extraocular disease, whereby decisions may involve palliation versus treatment secondary to the realities of limited resources, in which
case TTM may not be readily applied for this unique
context. In the particular setting where minimum resources are available (medical team and social support)
and where acceptance of enucleation versus ocular salvage represents the key defining step, TTM may then
be considered as an applicable theory. Using TTM, a
family can be described along a series of temporal dimensions in decisional acceptance and treatment readiness with the timeline redefined in retinoblastoma due to
urgency (Table 2).
Interventions at each stage primarily require creativity
and commitment of planners without necessarily requiring cost-intensive resources. Examples are outlined further below, with recognition that precise applications of
these social efficacy promotion efforts may vary depending on the maturity of the other health service delivery
interventions and context of the local health system.
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Figure 4 Precaution adoption process model applied to “social interventions” for earlier diagnosis of retinoblastoma in LMIS.

For transition from precontemplation to contemplation: This intervention engages with the family and
patient with information about the urgent need to start
treatment and provides personal information about
the risks of not receiving treatment. As part of the
consciousness-raising process, there is personalized education on cure and the consequences of no action. As
part of the dramatic relief process, there is opportunity
for personal testimonies from parent groups and pictures of orbital prosthesis cosmetic results shared with
parents. Awareness raising interventions should continually improve upon the local quality of orbital prostheses
through local partnerships with those experienced in sizing and placing orbital prosthesis with minimal infection
risks. As part of environmental reevaluation, parent networks model the potential for families to envision themselves serving as positive role models for others.
For transition from contemplation to preparation:
There is motivation and encouragement of the family to
set goals and make specific plans through one-on-one
sessions with the health team to include social workers
and psychologists. As part of self-reevaluation, there are
opportunities for meetings with parents of retinoblastoma survivors present to discuss the parental-image and
community-image and self-image of the child after enucleation. This provides opportunity for value clarification

and recognition of a successful life while visually impaired. “Family experts” (families who have a child retinoblastoma survivor member) can be available to discuss
overcoming acceptance barriers such as blindness stigma
and fear of cancer diagnosis.
For transition from preparation to action: The health
team helps the family to create and implement specific
action plans for treatment start and to set realistic goals
in terms of surgical outcome, and side effects of chemotherapy or radiation therapy if needed. Team members
involved in psychosocial health of the family or Child
Life teams, where available, become increasingly involved
to support the patient with age-appropriate medical interpretations of events (use of dolls to model what the
eye bandage will look, self-expression activities, and ageappropriate coping strategies).
For transition from action to treatment: Social support
and feedback are emphasized. Liberation, the belief that
treatment is attainable and the commitment to act on
that belief, is increasingly emphasized with family support sessions. For reinforcement management, therapeutic
relationships with social workers and overt reinforcements
for families to attend medical appointments may help
actualize verbal commitment to treatment. This stage
may introduce opportunities for group participation
in projects to promote rights/services for cancer patients
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Figure 5 Transtheoretical model (Linear) for retinoblastoma treatment. The linear model represents a staged progression from
precontemplation through maintenance. Maintenance in oncology care represents a starting point, as treatment completion through cure
(remaining actively “maintained” through treatment) is the ultimate goal.

and visually-impaired. This transition relies on helping
relationships based on therapeutic alliances whether
with parent support groups, counselor telephone calls,
and/or buddy systems among family networks. The maintained progression through treatment completion is an essential time to prevent abandonment of therapy. There
should be continued social support, assistance with problem solving, and intervention plans in place for missed appointments or delays in care. Supporting families at this

stage require creativity and resourcefulness to overcome
social, transportation, educational, and financial barriers
to treatment completion. This stage emphasizes reminder
systems and performance-support tools, which may involve a written calendar, text messaging reminder cues for
appointments, or home visits. Effective adherence data
tracking under the supervision of staff trained in adherence interventions allows for monitoring and recognition
of adherence.

Table 2 Transtheoretical model’s stages of change
Stage of change

Proposed definition

Precontemplation

Family has not started treatment and does not intend to start treatment in ___ weeks (number of weeks locally determined)
● Transition emphasis: acknowledgement of urgent need

Contemplation

Family intends to start treatment but is in a “behavioral procrastination” stage without plan in place to start treatment
● Transition emphasis: goal setting with focus on tangible plans to obtain goals

Preparation

Family has a plan of starting treatment in next days
● Transition emphasis: Establishment of specific steps to action

Action

Family has made specific modifications to their lifestyles in preparation to start treatment
● Transition emphasis: Community support and partnership

Maintenance

Family is actively in treatment and with intention to continue treatment
● Transition emphasis: Assistance with problem solving and interventions in place to support family through treatment completion

Weaver et al. BMC Public Health 2014, 14:944
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Family-efficacy and decisional-balance

Adaptation of proposed models

Progression between stages of readiness for treatment
initiation is not always lived out as a linear process and
may involve regression to a prior stage or abandonment
during a stage (Figure 6) [46]. Elements that can modulate the non-linearity of this process include family efficacy, or a family’s judgment regarding one’s ability to
perform a behavior (in this case, engagement in treatment) as required to achieve a certain outcome (cure).
Decisional balance, defined as the perceived benefits and
perceived barriers affecting health decisions, whether
financial, psychological, social, or physical, is also dynamic. The interdisciplinary care team should therefore
frequently survey the family’s sense of efficacy and decisional balance to proactively intervene to promote
healthy stage progression.

Each theory or model, ranging from social determinant
of health models to health behavior theories to Stages
of Change models, should be continually assessed and
tailored for optimized application in order to achieve
real-world results. The most effective approach to retinoblastoma outcomes in a particular setting will be a
framework that impacts all agents: health care policies
and insurance coverage, visually-impaired services in
medical and social institutions, and partnerships among
intra-disciplinary care teams, communities, families, and
patients. The most appropriate application of theories
and models will be a locally-selected, culturally-relevant,
pragmatic combination of strengths from a variety of
theories that best consider the multiple agents, external
factors, and internal influences. The goal is for applied

Figure 6 Reality of transtheoretical model (Lived) for retinoblastoma treatment legend: The spiral model represents the lived
experience as an often non-linear experience of delay to start, regressions, and recycling through stages. The lighter the shade, the
more mature the progression. Red in this model represents warning of abandonment as upfront treatment refusal or failure to complete therapy,
representing regression or a recycling backward in stage progression. Blue represents a forward movement. Green represents an intervention
which re-addresses family-efficacy and decisional balance to foster forward progression. Bold shades warrant additional support as patients may
feel vulnerable during the newness of entrance into a stage, embarrassed by regression, or even ashamed about returning to care due to regression
or recycling backward in stages.
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Table 3 Stages of change approach strengths and weaknesses
Approach

Strength

Weakness

Precaution Adaption Processes Model
(PAPM)

-Dichotomous model, practical for decision-making

-“Decision not to treat” may be viewed as unacceptable

-Incorporates a distinct unawareness stage (versus
unaware OR unengaged) with opportunity for
education

-Emphasis on reading materials/pamphlets may need
to be locally modified to literacy rates

-Removes assumptions about immediate readiness
for behavior

-Danger of evolving into a self-help model without
adequate support for change when the external
forces of poverty and conflicting priorities are the
reason for delay

Transtheoretical Model (TTM)

-Recognizes different families will be in different stages

-Challenge of measuring family’s exact stage of
placement

-Encourages inclusive, appropriately timed motivational
readiness interventions

-Does not always recognize broader social and physical
context

-Supports families between decisional stages toward
acceptance

-May unintentionally imply blame on a family, whereas
much of the impetus is a fractured system of care
delivery
-Common phrases such as “self” efficacy and “self”
realization may not be relevant in settings where
health behaviors and outcomes are communally based

Decision to not utilize stage- based
model

-Potentially streamlined decision-making
-Time and resources centralized to making treatment
available and accessible
-With limited funding sources, focuses resources on
specific, measurable biological outcomes such as
diagnostic accuracy and disease response

-Population characteristics, needs, and values may be
overlooked when community engagement is not
prioritized (available and accessible does not equal
acceptable, appropriate, or equitable)
-Risk imposition of an external “evidence based
approach” which is not taking local evidence and
local experience into consideration to facilitate service
or intervention adoption and sustainability
-Risk suboptimal allocation and mis-prioritization of
resources toward well-intentioned empiric efforts
that are however poorly aligned with target populations’
current stages of readiness for change

models to inspire and instill realistic, acceptable, measurable health improvement outcomes [47].
Each theory-based approach can bring particular
strengths and potential weaknesses (examples in Table 3)
and thus best practice requires adaptation and molding
for disease-specific applications. Future clinical studies
should consider such theory-informed analysis frameworks in addition to daily practice in contextualizing
local evidence, prioritizing frameworks and data-driven
actions based on the pertinent dominant stages for particular individuals and patient groups.

to treatment initiation, and treatment abandonment including refusal in certain LMIS. The reality of health service and social barriers to cure obliges us to avoid
placing ill-cast blame on families. Instead, a comprehensive programmatic framework that recognizes the lived
context of delay provides opportunity for partnership
and efficacy promotion. In striving to improve outcomes
globally for curable childhood cancer conditions such as
retinoblastoma, opportunity arises to include Stages of
Change models for treatment completion, within the
reality of lived cultural and cost contexts.

Summary: shared vision

Abbreviations
LMIS: Low- and middle- income settings; PAPM: Precaution adoption
process model; Rb: Retinoblastoma; SOC: Stages of change;
TTM: Transtheoretical model.

“It is a terrible thing to see and have no vision”.
Helen Keller
Retinoblastoma is often curable when diagnosed early
and treated appropriately, but the prognosis is fatal
when diagnosis is delayed and treatment is deferred [4].
Health service delivery-based interventions and community awareness interventions have proven helpful in decreasing lag times and improved survival outcomes, but
there remains a high rate of delay in diagnosis, lag time
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